General Information of Drug Combination (ID: DCSDS32)

Drug Combination Name
ABIRATERONE BIO-300
Indication
Disease Entry Status REF
Lung adenocarcinoma Investigative [1]
Component Drugs ABIRATERONE   DM8V75C BIO-300   DMJ7NVI
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: HOP-62
Zero Interaction Potency (ZIP) Score: 13.81
Bliss Independence Score: 8.68
Loewe Additivity Score: 3.55
LHighest Single Agent (HSA) Score: 8.73

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ABIRATERONE
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [2]
ABIRATERONE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Steroid 17-alpha-monooxygenase (S17AH) TTRA5BZ CP17A_HUMAN Modulator [5]
------------------------------------------------------------------------------------
ABIRATERONE Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1) OTZKVLVJ CP17A_HUMAN Decreases Activity [6]
Tissue factor (F3) OT3MSU3B TF_HUMAN Increases Expression [7]
Membrane cofactor protein (CD46) OTQ8NWJD MCP_HUMAN Increases Expression [8]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Decreases Response To Substance [9]
------------------------------------------------------------------------------------
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
Rheumatoid arthritis FA20 Phase 1 [4]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DCJ378D MOLT-4 Investigative [10]
Chronic myelogenous leukemia DCY4M3E K-562 Investigative [10]
Clear cell renal cell carcinoma DCY6Z1X TK-10 Investigative [10]
Glioma DCDBPMK SF-539 Investigative [10]
Plasma cell myeloma DC4LKRS RPMI-8226 Investigative [10]
Renal cell carcinoma DCXAJAQ UO-31 Investigative [10]
Breast adenocarcinoma DCGMH4G MDA-MB-468 Investigative [11]
Carcinoma DCVER8D RXF 393 Investigative [11]
Carcinoma DCZ7F0H MCF7 Investigative [11]
Colon carcinoma DCW9574 KM12 Investigative [11]
Adenocarcinoma DCOJUXG OVCAR3 Investigative [1]
Adenocarcinoma DCUQOL1 NCIH23 Investigative [1]
Adenocarcinoma DCEUISK A549 Investigative [1]
Adenocarcinoma DC4ROT5 SW-620 Investigative [1]
Adenocarcinoma DCH4V7Z HCT116 Investigative [1]
Adenocarcinoma DCX2JO5 HCC-2998 Investigative [1]
Adenocarcinoma DCDLZLP HCT-15 Investigative [1]
Adenocarcinoma DCPKYQB HT29 Investigative [1]
Amelanotic melanoma DCBGA2Q M14 Investigative [1]
Amelanotic melanoma DCBPDWP MDA-MB-435 Investigative [1]
Cutaneous melanoma DCJDGFG SK-MEL-28 Investigative [1]
High grade ovarian serous adenocarcinoma DCHJHEU OVCAR-5 Investigative [1]
High grade ovarian serous adenocarcinoma DCT80CC OVCAR-8 Investigative [1]
Lung adenocarcinoma DCCMCPF MDA-MB-231 Investigative [1]
Lung adenocarcinoma DC72CT0 NCI-H522 Investigative [1]
Melanoma DCHOEY1 MALME-3M Investigative [1]
Pleural epithelioid mesothelioma DCWA9WR NCI-H226 Investigative [1]
Prostate carcinoma DCFFW46 PC-3 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 28 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
3 Clinical pipeline report, company report or official report of Humanetics.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
6 A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21. J Enzyme Inhib Med Chem. 2006 Oct;21(5):547-56.
7 Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
8 Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 Sep 6;3(17):e121497. doi: 10.1172/jci.insight.121497. eCollection 2018 Sep 6.
9 Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
10 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
11 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.